Iyaswamy A, Krishnamoorthi S K, Liu Y W, Song J X, Kammala A K, Sreenivasmurthy S G, Malampati S, Tong B C K, Selvarasu K, Cheung K H, Lu J H, Tan J Q, Huang C Y, Durairajan S S K, Li M
Mr. & Mrs. Ko Chi-Ming Centre for Parkinson's Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Institute of Biopharmaceutical Sciences, National Yang Ming University, Taipei, Taiwan.
Front Pharmacol. 2020 Oct 30;11:584770. doi: 10.3389/fphar.2020.584770. eCollection 2020.
Alzheimer's disease (AD) is characterized by memory dysfunction, Aβ plaques together with phosphorylated tau-associated neurofibrillary tangles. Unfortunately, the present existing drugs for AD only offer mild symptomatic cure and have more side effects. As such, developments of effective, nontoxic drugs are immediately required for AD therapy. Present study demonstrates a novel role of Chinese medicine prescription Yuan-Hu Zhi Tong (YZT) in treating AD, and it has substantiated the effectiveness of YZT in two different transgenic mice models of AD, namely P301S tau and 3XTg-AD mice. Oral treatment of YZT significantly ameliorates motor dysfunction as well as promotes the clearance of aggregated tau in P301S tau mice. YZT improves the cognitive function and reduces the insoluble tau aggregates in 3XTg-AD mice model. Furthermore, YZT decreases the insoluble AT8 positive neuron load in both P301S tau and 3XTg-AD mice. Using microarray and the "Connectivity Map" analysis, we determined the YZT-induced changes in expression of signaling molecules and revealed the potential mechanism of action of YZT. YZT might regulate ubiquitin proteasomal system for the degradation of tau aggregates. The research results show that YZT is a potential drug candidate for the therapy of tau pathogenesis and memory decline in AD.
阿尔茨海默病(AD)的特征是记忆功能障碍、β淀粉样蛋白斑块以及与磷酸化tau相关的神经原纤维缠结。不幸的是,目前现有的用于治疗AD的药物仅能提供轻微的症状缓解,且副作用较多。因此,迫切需要开发有效且无毒的药物用于AD治疗。本研究证明了中药方剂元胡止痛(YZT)在治疗AD中的新作用,并在两种不同的AD转基因小鼠模型,即P301S tau小鼠和3XTg-AD小鼠中证实了YZT的有效性。口服YZT可显著改善P301S tau小鼠的运动功能障碍,并促进聚集tau的清除。YZT可改善3XTg-AD小鼠模型的认知功能,并减少不溶性tau聚集体。此外,YZT可降低P301S tau小鼠和3XTg-AD小鼠中不溶性AT8阳性神经元负荷。通过微阵列和“连接图谱”分析,我们确定了YZT诱导的信号分子表达变化,并揭示了YZT的潜在作用机制。YZT可能通过调节泛素蛋白酶体系统来降解tau聚集体。研究结果表明,YZT是治疗AD中tau病理和记忆衰退的潜在候选药物。